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Abstract: Introduction: Lung cancer is the most common cancer among men around the world. Today, by 
evaluating the expression of microRNA biomarkers, cancer cells can be detected in specific tissues. 
However, it's still controversy that the expression of let-7 in the prognosis of patients with lung 
cancer is informative. 
Material and Methods: A meta-analysis was performed by searching Google Scholar, PubMed, Sco-
pus, Web of Science, IranMedex, MEDLIB, IranDoc and Scientific Information Database(SID). All data 
were extracted from articles comparing prognosis in patients with lung cancer having low expres-
sion of let-7 with those having high expression. Pooled hazard ratios (HRs) and corresponding 95 
% confidence intervals (CIs) were calculated. Subgroup analyses were conducted for ethnicity.  
Results: A total of 1,370 cases of lung cancer were involved for this meta-analysis. The HR of low 
let-7 expression was 1.32 (95 % CI 0.68–2.58). A subgroup analysis was performed on ethnicity; 
combined HR was 1.56 (95 % CI 0.52–4.62) for Asians and 1.08 (95%CI 0.42–2.74) for non-Asians.  
Conclusion: There was no significant relationship between the expression of let-7 and lung cancer, 
let-7 might be a biomarker in Asian patients with favourable prognosis. Furthermore, with large-
scale investigations, useful prognostic microRNA biomarkers in the diagnosis, treatment and fol-
low-up could be detected. 
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1. Introduction 
 espite progress in diagnosis and treatment, 
lung cancer (LC) is one of the leading causes of 
death in the world (1). Due to age, population 
growth and high risk behaviours such as smoking, the 
incidence of respiratory cancers in the worldwide is still 
high. Until the early 20th century, lung cancer was a rare 
disease, but its prevalence increased sharply, so today it 
is one of the most common cancers. After breast cancer 
in women and prostate in men, lung cancer is the second 
common cancer with a ratio of 15% of all cancers and 
the first cause of cancer deaths in both genders (2, 3). In 
addition to genetic and environmental factors, 
epigenetic factors are also involved in the aetiology of 
cancer. Recently, it has been found that microRNAs are 
closely related to various diseases, including lung 
cancer. MicroRNAs are small non-coding RNAs that 
regulate the expression of the gene through the 
destruction of mRNA molecules or by preventing their 
translocation (4). The Let-7 family is a group of 
microRNAs that act as an oncogene and tumour 
suppressor genes. This family has 13 members 
including: Let-7a-1, Let-7a-2, Let-7a-3, Let-7b, Let-7c, 
Let-7d, Let-7e, Let-7f-1, Let-7f-2, Let-7g, Let-7i, mir-202, 
and mir-98. In most cancers, the expression of Let-7 is 
reduced, which results in its tumour-suppressive role 
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 (5, 6). Let-7, in many genes, is in the fragile region 
associated with cancer, and the report by Boyerinas et 
al. has revealed the first relationship between Let-7 and 
human cancers (7, 8). According to the previous 
literatures, it has been quite clear-cut that let-7 
expression is frequently reduced in lung cancer and that 
changes in the miRNA expression may have a prognostic 
impact on the survival of surgically treated lung cancer 
patients (9). 
In this meta-analysis, the relationship between 
expression of let‑7 and LC has been evaluated, to 
ultimately determine its efficacy as an invasive 
biomarker in detecting LC. 
 
2. Method 
2.1. Search strategy and Selection criteria: 
In an effort to retrieve the original Farsi and English lan-
guage papers about the expression of let-7 family and 
lung cancer, a systematic search was performed on in-
ternational and Iranian databases including Web of Sci-
ence, Proquest, Google Scholar, PubMed, Scopus, 
IranMedex, MEDLIB, IranDoc and Scientific Information 
Database (sid). All relevant papers which contained the 
selected key terms (expression analysis, hazard ra-
tio(HR) and lung cancer) and published until September 
2018, were included. The reference lists of the extracted 
articles were also checked to find other helpful sources. 
The selection of papers occurred firstly through the 
analysis of titles and abstracts/summaries. The analysis 
of the manuscripts followed the predetermined eligibil-
ity criteria for the inclusion criteria: (1) papers that had 
in the title at least a mixture of the terms outlined in the 
search strategy; (2) articles written in English or Farsi; 
(3) papers had been published and indexed in one of the 
above-mentioned databases.  
The elements excluded: (1) non-original studies such as 
Letters to the Editor, Prefaces, brief communication, 
Corrections/Editorials, and Monographs (2) Papers re-
peated in more than one database were counted just 
once (3) studies based on non-human research (4) lack 
of data information such as HR and 95% CI.  
2.2. Quality assessment and Data extraction: 
This study has been performed as a meta-analysis in ac-
cordance with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) state-
ment guidelines (www.prisma-statement.org). Two re-
viewers independently screened all potential titles, ab-
stracts of the identified studies and if needed, full-texts 
for eligibility. Disagreement for inclusion was resolved 
by discussion and consultation with a third reviewer 
during study selection and data extraction. Then, each 
sample item was read in its entirety, and the infor-
mation was recorded into a spreadsheet that included 
authors, year of publication, sample size, ethnicity, his-
totype, and statistical data.  Some of the papers found 
were focusing the theme of Let-7 and/or LC correlated 
to other type of cancers, diseases or polymorphisms, 
considering that this article focuses expression analysis 
of Let-7 and LC, correlated data to other elements were 
not analysed. Reference lists of all included full-text 
manuscripts were screened for additional articles. Au-
thors of papers were contacted to ask clarification 
where inadequate information was provided. 
2.3. Statistical analysis: 
Hazard ratio estimates LnHR and corresponding 95% CI 
for the association of LET-7 expression with overall sur-
Records identified through 
database searching             
(n=720)





Excluded: Topic not relevant and 
repeated cases  (n=31)
Studies included in systematic review
(n=9)










Figure 1: PRISMA flow chart for selecting relevant articles. 
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vival of lung cancer. The random effects model was ap-
plied to ensure the selection of more conservative esti-
mates. Moreover, hazard ratios (HRs) of individual stud-
ies were presented as forest plots. Chi-squared test, I2 
and Galbraith plot were used to assess statistical heter-
ogeneity and heterogeneity plot. The p-values less than 
0.05 suggested statistically significant heterogeneity in 
Chi-squared test. In order to measure publication bias, 
funnel plots of precision and standard error against log 
(HR) were developed. Begg’s rank correlation and Eg‑
ger’s regression intercept were also carried out to eval‑




Following the above-mentioned procedure (Figure 1), 
720 papers were extracted at the initial phase of their 
work. Of these, 9 articles were finally retrieved and an-
alysed (Table 1). A total of 1,370 cases of lung cancer 
were collected in this meta-analysis. The HR of low let-
7 expression in lung cancer was (1.32,95 % CI 0.68–
2.58), (Figure 2). Forest plot analysis indicated the het-
erogeneity of the let-7 expression in lung cancer (Figure 
2). All nine studies reported data that allowed for the 
calculation of overall survival.  The main information of 
these studies is shown in Table 1. Meanwhile, as shown 
in figure 3, there was enough evidence indicating the 
presence of publication bias; Begg’s rank correlation 
analysis, z = 0.00; p-value >0.05 (Figure 3) and Egger’s 
regression intercept (Figure 4).  The method for investi-
gating the expression of let-7 was quantitative real-time 
PCR. Empirically, HR of less than 1.5 is considered as a 
weak prognostic factor (10). The combined analysis of 
the nine studies showed that let-7 low expression was 
not associated with overall survival (z=0.83 p = 0.40), 
and the heterogeneity (I2 statistic) was 88.6 % (Figure 
2), chi-squared =70.16 (df. = 8) p = 0.000, and Galbraith 
plot showed a high heterogeneity(Figure 5).  Then a 
subgroup analysis was performed on ethnicity; no asso-
ciation of let-7 expression and survival was evident 
(1.56,95 % CI 0.52–4.62); (z=0.81, p = 0.42) and 
(1.08,95 % CI 0.42–2.74); (z=0.17 p = 0.86) for Asians 




More research is needed to clarify the regulatory mech-
anisms for the biogenesis of microRNAs and their role 
in cancer. Diagnosis of target microRNA and the study of 
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help to better understand the nature of cancer. Consid-
ering the fact that the most common methods for 
screening cancer in the early stages are not able to diag-
nose the disease, identification of tumour microRNAs 
that spread through blood during gradual progression 
of the disease is a key to early diagnosis of cancer. In ad-
dition, microRNAs are also used to treat cancer, and 
making effective changes to these molecules can affect 
their targets (4, 20). In a study by Lee et al, the effect of 
Let-7g on tumour inhibition has been proven. Its ex-
pression in lung cancer cells results in a decrease in the 
expression of HMGA2 oncogene and reduction of cell 
proliferation (21). Boyerinas et al. demonstrated the 
role of the Let-7 as an oncogene and by using the mouse 
lung cancer model, confirmed the tumour suppressor 
function of Let-7 with Ras gene inactivation. In humans, 
a significant reduction in the expression of the Let-7 
family has been reported in many cancers such as; co-
lon, stomach, and melanoma, in the lung cancer, the re-
duction of expression of Let-7g has been inversely re-
lated to survival. On the other hand, Let-7a injections 
into mice with lung cancer lead to a decrease in tumour 
growth, and so this gene can be considered as a thera-
peutic potential for the treatment of lung cancer (22, 
23). In 2014, Xia et al investigate the low expression of 
Let-7 with various types of cancers and illustrated that 
low expression of let-7 was significantly associated with 
poor prognosis in tumours (6). In another study, 
Lamichhane et al performed a meta-analysis (n = 1,239) 
and reported a significant low expression of let-7with 
poor prognosis and overall survival (1.94, 95% CI: 0.87-
4.32) in NSCLC (9). At present, there is not enough data 
to confirm the informative biomarkers of microRNAs in 
lung cancer. As a result, despite the many advances in 
the genetic and epigenetic aspects of lung cancer, there 
are still no accurate biomarkers that can be used to 
prognosis and predict the results of chemotherapy and 
survival of patients (24, 25). In addition, there are sev-
eral limitations for this meta-analysis: Non-English and 
 














Figure 2: Forest plot of the relationship between ex-
pression of let-7 and lung cancer (overall survival) 
included in the meta-analysis. 
NOTE: Weights are from random effects analysis






































Figure 3: Begg’s funnel plot with 95%CI for publica‑
tion bias testing. 
 
 
Figure 4: Egger’s plot with 95%CI for publication 
bias testing. 
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Farsi articles and that did not have important survival 
information (eg, HR, CI or SE) were deleted and the 
number of studies available were limited. As previously 
mentioned, there are statistical heterogeneous articles 
for a variety of reasons, including differences in patient 
clinic pathological characteristics, geographical distri-
bution and different assay method. In summary, this ar-
ticle is not entirely complete due to heterogeneity, bias, 
and limitations, but the purpose of this article was to re-
 
Figure 6: Forest plot of survival data from Asia. 
NOTE: Weights are from random effects analysis


























Figure 7: Forest plot of survival data from non-Asia. 
NOTE: Weights are from random effects analysis
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view the LET-7 as a prognostic biomarker for lung can-
cer. Taken together, expression of let-7 was not signifi-




In general, microRNAs can be an important tool in early 
diagnosis and prognosis. It is also possible to use these 
molecules to design and treat the cancers. Considering 
that in our study there was no meaningful relationship 
between the expression of let-7 and lung cancer, it is 
hoped that in the future, with large-scale and standard 
studies and more sample size, an informative biomarker 
designed to help determine the type of treatment and 
the prognosis of cancer.  
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